Screener
Capricor Therapeutics CAPR EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Capricor Therapeutics’s reported figures.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
FAQ
- What is Capricor Therapeutics's EBITDA?
- Capricor Therapeutics (CAPR) reported EBITDA of -$36.24M in Q1 2026.
- How has Capricor Therapeutics's EBITDA changed year-over-year?
- Capricor Therapeutics's EBITDA decreased by 47.4% year-over-year, from -$24.58M to -$36.24M.
- What is the long-term trend for Capricor Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Capricor Therapeutics's EBITDA has grown at a 50.5% compound annual growth rate (CAGR), from -$20.69M to -$106.25M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Capricor Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude